Generic Name and Formulations:
Cefepime (as HCl) 500mg, 1g, 2g; pwd for IV infusion or IM inj after reconstitution.
Indications for MAXIPIME:
Susceptible infections, including moderate-to-severe pneumonia, uncomplicated skin and skin structure infections, complicated and uncomplicated urinary tract infections (UTIs) including pyelonephritis, complicated intraabdominal in adults (w. metronidazole). Empiric therapy in febrile neutropenia.
When giving IV, infuse over 30mins. Pneumonia: 1–2g IV every 8–12hrs for 10 days. Skin and skin structures, severe UTIs: 2g IV every 12hrs for 10 days. Mild-to-moderate UTIs: 500mg–1g IV or IM every 12hrs for 7–10 days (IM only for UTIs caused by E. coli). Intraabdominal (use w. metronidazole): 2g IV every 8–12hrs for 7–10 days. Febrile neutropenia: 2g IV every 8hrs for 7 days or until neutropenia resolves. CrCl ≤60mL/min: reduce dose; see full labeling. Hemodialysis: give dose after each session. Continuous ambulatory peritoneal dialysis: give usual doses at 48hr intervals.
<2mos: not established. Not for use in serious infection when pathogen is or may be H. influenzae type b. 2mos–16yrs (≤40kg): 50mg/kg/dose every 12hrs (every 8hrs for P. aeruginosa pneumonia); do not exceed recommended adult dose. Severe UTIs, pneumonia, skin and skin structure: give IV for 10 days. Mild-to-moderate UTIs: give IV or IM for 7–10 days (IM only for UTIs caused by E. coli). Febrile neutropenia: give IV every 8hrs for 7 days or until neutropenia resolves.
Penicillin or other β-lactam allergy.
Renal impairment. Risk of neurotoxicity (esp. in renally-impaired); discontinue if occurs and treat appropriately. Renal or hepatic dysfunction, poor nutritional state, prolonged antimicrobial therapy: monitor prothrombin time. History of GI disease (esp. colitis). Labor & delivery. Pregnancy (Cat.B). Nursing mothers.
Aminoglycosides may potentiate oto- or nephrotoxicity. Possible nephrotoxicity with diuretics (eg, furosemide). May cause false (+) Coomb's, Clinitest.
Local reactions (eg, pain, phlebitis, inflammation), rash, nausea, vomiting, diarrhea, pruritus, fever, headache, anemia, renal dysfunction; neurotoxicity, C. difficile associated diarrhea, hypersensitivity reactions.
Vials (500mg)—10; 1g, 2g—10, 25
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Adjunctive Therapies for Bipolar Disorder Show Promise, Need More Evidence
- Predicting Treatment-Emergent Mania to Tailor Pharmacotherapy in Bipolar Disorder
- Antidepressants Increase Seizure Risk in Youth and Severely Depressed
- Researchers Identify Novel Potential Biomarkers for Autism
- Abnormalities of Cortical Thickness in Bipolar Disorder With Auditory Hallucinations
- The Way to the Head May Be Through the Gut: Probiotics for Depression
- Suicide-Screening Toolkit Can Help Identify Youths at High Risk for Suicide
- Agoraphobia: An Evolving Understanding of Definitions and Treatment
- Parental Pressure to Diet Linked With Long-term Harm in Adolescents
- Does Access to Medical Cannabis Reduce Risk for Opioid Abuse?
- Triiodothyronine in the Treatment of Bipolar Depression
- Suicide Risk After Self-Harm Among Adolescents, Young Adults
- E-Cigarettes Associated With More Harms Than Benefits at Population Level
- Safety, Efficacy of Deep Brain Stimulation for Alzheimer Disease Examined
- Many Teens Who Use Tobacco Don't Self-Identify as Users